NAGE
Niagen Bioscience, Inc.
2.70$
+0.4%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +63.9% | -54.5% | -189.5% | – | +145.6% | -8.2% | -84.1% | +195.4% | -81.6% | -275.8% | – | – | |
| – | -16.7% | +4.6% | -5.1% | -1.1% | -2.2% | +2.8% | -3.5% | +1.1% | +2.5% | +26.1% | +1.3% | – | |
| – | -7.2% | -5.1% | +20.4% | -38.0% | +2.3% | +43.0% | +38.4% | +18.0% | -0.5% | -1.8% | +0.4% | – | |
| – | – | – | – | – | +932.6% | -47.1% | -256.7% | – | – | – | – | – | |
| – | -19.2% | +95.2% | -70.7% | +241.7% | +68.3% | -53.6% | +321.9% | -82.2% | +320.8% | -39.6% | +45.9% | – | |
| – | -19.2% | +95.2% | -70.7% | +75.0% | +228.6% | -53.6% | +321.9% | -82.2% | +320.8% | – | -101.8% | – | |
| – | – | – | – | – | – | – | – | – | – | +837.8% | +17.5% | – | |
| – | – | – | – | – | -50.0% | +50.0% | +0.0% | +33.3% | -50.0% | -100.0% | – | – | |
| – | +2,433.3% | -81.6% | – | +74.3% | +260.7% | -17.2% | +20.5% | -96.0% | -154.1% | +2,762.5% | +8.7% | – | |
| – | +50.4% | -56.5% | +33.3% | +1,310.3% | +171.7% | -10.7% | -55.7% | -21.4% | -86.9% | +253.6% | -89.2% | – | |
| – | +69.7% | -59.6% | -208.7% | – | +146.5% | -7.8% | -85.8% | +229.0% | -84.2% | -317.1% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.